UK MHRA grants marketing authorization to Sanofi’s rilzabrutinib to treat adults with immune thrombocytopenia when prior treatments have been insufficient: United Kingdom Monday ...

The immune thrombocytopenia market is experiencing steady growth driven by increasing disease awareness and improved diagnosis rates. Advancements in targeted therapies, including thrombopoietin ...

Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), ...

The American Red Cross reports a sharp drop in blood donations as the nation enters the critical summer trauma season.

The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.

Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 ...

Glucagon-like peptide-1 receptor agonists, aka GLP-1s, are one of the best-known synthetic peptides and the active ingredient ...

After an acute myeloid leukemia diagnosis, Robert Hines reached remission and received a lifesaving stem cell transplant from ...

ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose –– ...

As with any medicine, the MHRA will keep the safety and effectiveness of rilzabrutinib under close review. The Medicines and Healthcare products Regulatory Agency (MHRA) has today (29 May 2026) ...

A single enzyme inside liver cells drives the production of triglycerides that, in excess, fuel the inflammation and scarring ...